Portal de Periódicos da CAPES

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

2022; Multidisciplinary Digital Publishing Institute; Volume: 29; Issue: 3 Linguagem: Inglês

10.3390/curroncol29030150

1718-7729

Hamid Mithoowani, Michela Febbraro,

Cancer Immunotherapy and Biomarkers

Lung cancer is the leading cause of cancer death in Canada and a significant cause of morbidity for patients and their loved ones. There have been rapid advances in preventing, screening and treating this disease. Here, we present a contemporary review of treatment of non-small cell lung cancer in Canada based on current best practices. The focus of this review is to highlight recent data in screening for lung cancer, management of patients with early and locally-advanced non-small cell lung cancer, as well as management of patients with metastatic disease. There is a special focus on the incorporation of immunotherapy into practice and its associated toxicities.